Entrada Therapeutics, Inc. Overview
Pro stress-test →Entrada Therapeutics is a clinical-stage biopharmaceutical company developing Endosomal Escape Vehicle (EEV)-therapeutics designed to enable efficient intracellular delivery of therapeutics into various organs and tissues. The company is advancing RNA- and protein-based programs for neuromuscular and ocular diseases.
Strategic Profile
Pro stress-test →Entrada's primary focus is Duchenne muscular dystrophy (DMD), with Phase 1/2 studies of ENTR-601-44 and ENTR-601-45, and planned development of ENTR-601-50 and ENTR-601-51. The company gained FDA Rare Pediatric Disease Designation for ENTR-601-44 and ended 2025 with $295.7M in cash with runway into Q3 2027.
Competitive Landscape
Pro stress-test →In the rare disease biotech space, Entrada competes alongside companies such as Kymera Therapeutics, Kodiak Sciences, and other clinical-stage biopharma firms. Entrada's proprietary EEV technology provides differentiation in intracellular drug delivery, a less crowded segment compared to traditional monoclonal antibodies or small molecules, positioning it uniquely for intracellular target engagement.
Industry Context
Entrada Therapeutics, Inc. operates in Clinical-stage biopharmaceutical (rare neuromuscular and ocular diseases).
Key facts
Founded: 2016 · Headquarters: Boston, Massachusetts · Employees: null · Revenue: Minimal (collaboration-dependent) · Market cap: $456M